Table 1 Demographics, cardiovascular risk factors, respiratory function, chronic lung infections and medications of patients enrolled in this study
Study population n = 22 | |
|---|---|
Demographics, n (%) | |
Age, median (IQR) years | 33 (24–51) |
Female | 11 (50) |
Body mass index, median (IQR) | 20.8 (18.2–23.9) |
Lung Allocation Score, median (IQR) | 34.6 (32.8–38.6) |
Cystic fibrosis | 14 (63.6) |
Idiopathic pulmonary fibrosis | 2 (9.1) |
Chronic obstructive pulmonary disease | 2 (9.1) |
Nonspecific interstitial pneumonia | 1 (4.5) |
Other indications for lung transplant | 3 (13.6) |
Cardiovascular risk factors, n (%) | |
Hypertension | 4 (18.2) |
Diabetes | 10 (45.5) |
Pulmonary hypertension | 5 (22.7) |
mPAP, median (IQR) mmHg | 21.5 (18–24) |
Respiratory function, median (IQR) | |
Exacerbations, n (%) | 16 (72.7) |
P/F | 319 (279–342) |
pCO2, mmHg | 41 (38.8–48) |
FEV1% of predicted | 28.5 (24–43) |
FVC % of predicted | 53 (40–64) |
FEV1/FVC ratio | 49.5 (41–69) |
DLCO, % | 45 (28–57) |
6MWT, m | 475 (255–540) |
Chronic lung infections, n (%) | |
P. aeruginosa | 12 (54.5) |
MRSA | 6 (27.3) |
Aspergillus | 2 (9.1) |
C. albicans | 2 (9.1) |
B. cepacia | 1 (4.5) |
Medications, n (%) | |
Beta-agonists | 20 (90.9) |
Steroids | 18 (81.8) |
Oxygen | 16 (72.7) |
Beta-blockers | 3 (13.6) |